Impax Asset Management Group plc Has $16.39 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Impax Asset Management Group plc boosted its stake in Zoetis Inc. (NYSE:ZTS) by 48.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 100,615 shares of the company’s stock after buying an additional 32,833 shares during the period. Impax Asset Management Group plc’s holdings in Zoetis were worth $16,393,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Mizuho Securities USA LLC grew its position in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after purchasing an additional 665,331 shares during the last quarter. Nordea Investment Management AB boosted its stake in Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Holocene Advisors LP bought a new stake in shares of Zoetis during the third quarter worth $110,809,000. Finally, Fisher Funds Management LTD acquired a new stake in shares of Zoetis in the fourth quarter valued at $66,123,000. 92.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Finally, Piper Sandler decreased their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $215.40.

Zoetis Stock Performance

Shares of Zoetis stock opened at $165.51 on Tuesday. The firm has a fifty day moving average of $166.30 and a two-hundred day moving average of $177.78. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market capitalization of $74.12 billion, a price-to-earnings ratio of 30.26, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s dividend payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.